Skip to content
drillr.ai
Sign up

ADAG

Adagene, Inc.

NASDAQ · Healthcare · Biotechnology · CN

$2.29
+11.17%
Ask drillr

  • Sep 22, 2026, 12:00 UTC

    China's National Medical Products Administration approved Adagene's investigational new drug application for ADG138, a double-masked HER2xCD3 bispecific T-cell engager, with a Phase 1 study in advanced solid tumors expected to begin in China in Q4 2026.

    Source:

  • Sep 10, 2026, 12:00 UTC

    Third Arc Bio selected its first lead candidate under an amended strategic collaboration with Adagene for the development of masked CD3 T cell engagers utilizing Adagene's SAFEbody technology.

    Source: